Search

Your search keyword '"Traboulsee, Anthony"' showing total 1,070 results
Start Over Author "Traboulsee, Anthony"
1,070 results on '"Traboulsee, Anthony"'

1. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.

Author

Kappos, Ludwig, Traboulsee, Anthony, Li, David, Bar-Or, Amit, Barkhof, Frederik, Montalban, Xavier, Leppert, David, Baldinotti, Anna, Schneble, Hans-Martin, Koendgen, Harold, Sauter, Annette, Wang, Qing, and Hauser, Stephen

Subjects
Disease-modifying therapies, Multiple sclerosis, Ocrelizumab, Safety, Humans, Antibodies, Monoclonal, Humanized, Immunologic Factors, Interferon beta-1a, Multiple Sclerosis, Relapsing-Remitting, Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic
Abstract

Open-label extension (OLE) studies help inform long-term safety and efficacy of disease-modifying therapies in multiple sclerosis (MS). We report exploratory analyses from a phase 2 trial on the longest follow-up to date of ocrelizumab-treated patients with relapsing-remitting MS (RRMS). The primary treatment period (PTP) comprised four 24-week treatment cycles; participants were randomized to double-blind ocrelizumab (2000 mg or 600 mg), placebo, or interferon β-1a (open label) for one cycle, then dose-blinded ocrelizumab 1000 mg or 600 mg for the remaining cycles. The PTP was followed by consecutive assessed and unassessed treatment-free periods (TFPs) and then the OLE (ocrelizumab 600 mg every 24 weeks). Safety and efficacy were prospectively assessed. Of 220 participants randomized, 183 (84%) completed the PTP. After the TFP, 103 entered OLE (median OLE ocrelizumab exposure 6.5 years). Most common adverse events across all periods were infusion-related reactions. MRI activity, annualized relapse rate, and confirmed disability progression (CDP) rates remained low throughout. During the assessed TFP, there was a trend toward less and later B-cell repletion, and later CDP, for patients randomized to ocrelizumab; MRI activity was observed in 16.3% of patients, the earliest 24 weeks after the last ocrelizumab dose. This is the longest follow-up of ocrelizumab-treated patients with RRMS, with no new safety signals emerging during an observation period from 2008 to 2020. Results reinforce the sustained efficacy of long-term ocrelizumab. Reduced disease activity was maintained following interruption of 6-month dosing cycles, with no evidence of rebound.

Published
2024

4. Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Author

Hauser, Stephen L, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Brochet, Bruno, Naismith, Robert T, Traboulsee, Anthony, Wolinsky, Jerry S, Belachew, Shibeshih, Koendgen, Harold, Levesque, Victoria, Manfrini, Marianna, Model, Fabian, Hubeaux, Stanislas, Mehta, Lahar, and Montalban, Xavier

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Neurosciences, Brain Disorders, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Neurological, Adult, Antibodies, Monoclonal, Humanized, Brain, Female, Follow-Up Studies, Humans, Immunologic Factors, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Relapsing-Remitting, Neuroimaging, Randomized Controlled Trials as Topic, Recurrence, Time Factors, Treatment Outcome, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo assess over 3 years of follow-up the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE) phase of the pooled OPERA: I/II studies in relapsing multiple sclerosis.MethodsAfter 2 years of double-blind, controlled treatment, patients continued OCR (600 mg infusions every 24 weeks) or switched from interferon (IFN)-β-1a (44 μg 3 times weekly) to OCR when entering the OLE phase (3 years). Adjusted annualized relapse rate, time to onset of 24-week confirmed disability progression (CDP)/improvement (CDP), brain MRI activity (gadolinium-enhanced and new/enlarging T2 lesions), and percentage brain volume change were analyzed.ResultsOf patients entering the OLE phase, 88.6% completed year 5. The cumulative proportion with 24-week CDP was lower in patients who initiated OCR earlier vs patients initially receiving IFN-β-1a (16.1% vs 21.3% at year 5; p = 0.014). Patients continuing OCR maintained and those switching from IFN-β-1a to OCR attained near complete and sustained suppression of new brain MRI lesion activity from years 3-5. Over the OLE phase, patients continuing OCR exhibited less whole brain volume loss from double-blind study baseline vs those switching from IFN-β-1a (-1.87% vs -2.15% at year 5; p < 0.01). Adverse events were consistent with past reports and no new safety signals emerged with prolonged treatment.ConclusionCompared with patients switching from IFN-β-1a, earlier and continuous OCR treatment up to 5 years provided sustained benefit on clinical and MRI measures of disease progression.Classification of evidenceThis study provides Class III evidence that earlier and continuous treatment with OCR provided sustained benefit on clinical and MRI outcomes of disease activity and progression compared with patients switching from IFN-β-1a. The study is rated Class III because of the initial treatment randomization disclosure that occurred after inclusion in OLE.Clinical trial identifiersNCT01247324/NCT01412333.

Published
2020

5. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial

Author

Traboulsee, Anthony, Greenberg, Benjamin M, Bennett, Jeffrey L, Szczechowski, Lech, Fox, Edward, Shkrobot, Svitlana, Yamamura, Takashi, Terada, Yusuke, Kawata, Yuichi, Wright, Padraig, Gianella-Borradori, Athos, Garren, Hideki, and Weinshenker, Brian G

Subjects
Patient Safety, Neurosciences, Eye Disease and Disorders of Vision, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Neuromyelitis Optica, Treatment Outcome, Young Adult, Clinical Sciences, Neurology & Neurosurgery
Abstract

BackgroundSatralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy. This study assessed the safety and efficacy of satralizumab monotherapy in patients with the disorder.MethodsIn this phase 3, double-blind, placebo-controlled, parallel-group trial, we enrolled adults aged 18-74 years with aquaporin-4 antibody seropositive or seronegative NMOSD at 44 investigational sites in 13 countries. Eligible participants had experienced at least one documented NMOSD attack or relapse in the past 12 months and had a score of 6·5 or less on the Expanded Disability Status Scale. Exclusion criteria included clinical relapse 30 days or fewer before baseline. Participants were randomly assigned (2:1) to receive satralizumab 120 mg or visually matched placebo subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter. Taking immunosuppressants concomitantly was prohibited. The primary endpoint was time to the first protocol-defined relapse, based on the intention-to-treat population and analysed with stratification for two randomisation factors (previous therapy for prevention of attacks and nature of the most recent attack). Safety was assessed in all participants who received at least one dose of satralizumab or placebo. The double-blind phase was due to last until 44 protocol-defined relapses occurred or 1·5 years after random assignment of the last patient enrolled, whichever occurred first; participants could enter an open-label phase after the occurrence of a protocol-defined relapse or at the end of the double-blind phase. The study is registered with ClinicalTrials.gov, NCT02073279.Findings95 (57%) of 168 screened participants were randomly assigned to treatment (63 to satralizumab; 32 to placebo) between Aug 5, 2014, and April 2, 2017. Protocol-defined relapses occurred in 19 (30%) patients receiving satralizumab and 16 (50%) receiving placebo (hazard ratio 0·45, 95% CI 0·23-0·89; p=0·018). 473·9 adverse events per 100 patient-years occurred in the satralizumab group, as did 495·2 per 100 patient-years in the placebo group; the incidence of serious adverse events and adverse events leading to withdrawal was similar between groups.InterpretationSatralizumab monotherapy reduced the rate of NMOSD relapse compared with placebo in the overall trial population, with a favourable safety profile. The patient population included a ratio of aquaporin-4 antibody seropositive and seronegative patients that was reflective of clinical practice. Satralizumab has the potential to become a valuable treatment option for patients with NMOSD.FundingChugai Pharmaceutical (Roche).

Published
2020

6. Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS.

Author

Oh, Jiwon, Ontaneda, Daniel, Azevedo, Christina, Klawiter, Eric C, Absinta, Martina, Arnold, Douglas L, Bakshi, Rohit, Calabresi, Peter A, Crainiceanu, Ciprian, Dewey, Blake, Freeman, Leorah, Gauthier, Susan, Henry, Roland, Inglese, Mathilde, Kolind, Shannon, Li, David KB, Mainero, Caterina, Menon, Ravi S, Nair, Govind, Narayanan, Sridar, Nelson, Flavia, Pelletier, Daniel, Rauscher, Alexander, Rooney, William, Sati, Pascal, Schwartz, Daniel, Shinohara, Russell T, Tagge, Ian, Traboulsee, Anthony, Wang, Yi, Yoo, Youngjin, Yousry, Tarek, Zhang, Yunyan, Sicotte, Nancy L, and Reich, Daniel S

Subjects
Brain Disorders, Neurodegenerative, Clinical Research, Biomedical Imaging, Multiple Sclerosis, Clinical Trials and Supportive Activities, Autoimmune Disease, Neurosciences, Neurological, Brain, Diffusion Tensor Imaging, Humans, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopy, Multimodal Imaging, Nerve Regeneration, Neuroprotection, Outcome Assessment, Health Care, Positron-Emission Tomography, Spinal Cord, North American Imaging in Multiple Sclerosis Cooperative, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo summarize current and emerging imaging techniques that can be used to assess neuroprotection and repair in multiple sclerosis (MS), and to provide a consensus opinion on the potential utility of each technique in clinical trial settings.MethodsClinicians and scientists with expertise in the use of MRI in MS convened in Toronto, Canada, in November 2016 at a North American Imaging in Multiple Sclerosis (NAIMS) Cooperative workshop meeting. The discussion was compiled into a manuscript and circulated to all NAIMS members in attendance. Edits and feedback were incorporated until all authors were in agreement.ResultsA wide spectrum of imaging techniques and analysis methods in the context of specific study designs were discussed, with a focus on the utility and limitations of applying each technique to assess neuroprotection and repair. Techniques were discussed under specific themes, and included conventional imaging, magnetization transfer ratio, diffusion tensor imaging, susceptibility-weighted imaging, imaging cortical lesions, magnetic resonance spectroscopy, PET, advanced diffusion imaging, sodium imaging, multimodal techniques, imaging of special regions, statistical considerations, and study design.ConclusionsImaging biomarkers of neuroprotection and repair are an unmet need in MS. There are a number of promising techniques with different strengths and limitations, and selection of a specific technique will depend on a number of factors, notably the question the trial seeks to answer. Ongoing collaborative efforts will enable further refinement and improved methods to image the effect of novel therapeutic agents that exert benefit in MS predominately through neuroprotective and reparative mechanisms.

Published
2019

7. Cortical morphology predicts placebo response in multiple sclerosis

Author

Cherkasova, Mariya V., Fu, Jessie F., Jarrett, Michael, Johnson, Poljanka, Abel, Shawna, Tam, Roger, Rauscher, Alexander, Sossi, Vesna, Kolind, Shannon, Li, David K. B., Sadovnick, A. Dessa, Machan, Lindsay, Girard, J. Marc, Emond, Francois, Vosoughi, Reza, Traboulsee, Anthony, and Stoessl, A. Jon

Published
2022
Full Text
View/download PDF

8. Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.

Author

Scalfari, Antonio, Traboulsee, Anthony, Oh, Jiwon, Airas, Laura, Bittner, Stefan, Calabrese, Massimiliano, Garcia Dominguez, Jose Manuel, Granziera, Cristina, Greenberg, Benjamin, Hellwig, Kerstin, Illes, Zsolt, Lycke, Jan, Popescu, Veronica, Bagnato, Francesca, and Giovannoni, Gavin

Subjects
*CEREBROSPINAL fluid, *MULTIPLE sclerosis, *PATIENTS' attitudes, *DRUG target, *CLINICAL trials
Abstract

Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition of "progression independent of relapsing activity." We propose the concept of smouldering‐associated‐worsening (SAW), encompassing physical and cognitive symptoms, resulting from smouldering pathological processes, which remain unmet therapeutic targets. We provide a consensus‐based framework of possible pathological substrates and manifestations of smouldering MS, and we discuss clinical, radiological, and serum/cerebrospinal fluid biomarkers for potentially monitoring SAW. Finally, we share considerations for optimizing disease surveillance and implications for clinical trials to promote the integration of smouldering MS into routine practice and future research efforts. ANN NEUROL 2024;96:826–845 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics.

Author

Oh, Jiwon, Arbour, Nathalie, Giuliani, Fabrizio, Guenette, Melanie, Kolind, Shannon, Lynd, Larry, Marrie, Ruth Ann, Metz, Luanne M., Prat, Alexandre, Schabas, Alice, Smyth, Penelope, Tam, Roger, Traboulsee, Anthony, Yong, Voon Wee, and Patten, Scott B.

Subjects
MULTIPLE sclerosis, LONGITUDINAL method, COHORT analysis, INTELLECTUAL disabilities, CERVICAL cord, MAGNETIC resonance imaging, SPINAL cord injuries
Abstract

Background: Disease progression is observed across the spectrum of people with multiple sclerosis (MS) and identification of effective treatment strategies to halt progression remains one of the greatest unmet clinical needs. Objectives: The Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) was designed to evaluate a wide range of factors associated with the onset and rate of clinical disease progression in MS and to describe the interplay between these factors. Design: A prospective cohort study. Methods: CanProCo is a national, prospective, observational cohort study that has recruited 944 individuals from 5 large academic MS centers in Canada. Participants include people with radiologically isolated syndrome (RIS), early relapsing-remitting and primary progressive MS (RRMS, PPMS), and healthy controls (HCs). Annually, participants complete self-reported questionnaires, undergo clinical evaluation and, if clinically indicated, magnetic resonance images (MRIs) of the brain and cervical spinal cord; in a subset of participants (n = 399), blood, and research MRIs of the brain and cervical spinal cord are collected. Linkages to health administrative databases are available at three sites. Results: Overall, 944 participants were recruited (53 HCs, 63 RIS, 751 RRMS, 77 PPMS). RIS and MS participants had a mean age of 39.0 years and 70.5% female. The mean time since diagnosis was 2.7 years. There were differences observed in the Expanded Disability Status Scale score and components of the MS performance test (walking speed test, manual dexterity test, processing speed test, and low-contrast visual acuity) between RIS and MS subtypes. Questionnaires revealed more symptoms of depression and anxiety and impaired physical and mental quality of life in people with RIS/MS versus HCs and differences across RIS/MS subtypes. Conclusion: Physical and mental neurological disability is prevalent even in the earliest stages of MS. Transdisciplinary approaches such as those used in CanProCo are needed to better characterize clinical progression in MS. Additional CanProCo results, including MRI, biological, and pharmaco-economic data will be forthcoming. Going forward, CanProCo's data sharing and collaborative vision will facilitate numerous global collaborations, which will inform the development and implementation of effective interventions for people with MS around the world. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

Author

Havrdová, Eva, Arnold, Douglas L, Bar-Or, Amit, Comi, Giancarlo, Hartung, Hans-Peter, Kappos, Ludwig, Lublin, Fred, Selmaj, Krzysztof, Traboulsee, Anthony, Belachew, Shibeshih, Bennett, Iain, Buffels, Regine, Garren, Hideki, Han, Jian, Julian, Laura, Napieralski, Julie, Hauser, Stephen L, and Giovannoni, Gavin

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Brain Disorders, Multiple Sclerosis, Clinical Trials and Supportive Activities, Clinical Research, Neurodegenerative, Neurosciences, Autoimmune Disease, MRI activity, NEDA, disability progression, disease activity, relapse, Epidemiology, Health services and systems
Abstract

BackgroundNo evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS).ObjectiveThe objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status.MethodsNEDA was assessed in a modified intent-to-treat population (n = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg).ResultsNEDA was increased with ocrelizumab vs IFN β-1a over 96 weeks by 75% (p

Published
2018

12. Health Canada drug approval process: a barrier to personalized care in multiple sclerosis

Author

Oh, Jiwon, primary, Bhan, Virender, additional, Traboulsee, Anthony, additional, Morrow, Sarah A., additional, Lee, Liesly, additional, Levin, Michael, additional, Casserly, Courtney, additional, Freedman, Mark S., additional, Giacomini, Paul S., additional, Émond, François, additional, Smyth, Penelope, additional, Clift, Fraser, additional, and Selchen, Daniel, additional

Published
2024
Full Text
View/download PDF

13. Long-term Efficacy of Satralizumab in Patients with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Updated Analysis from the Open-label SAkuraMoon Study (S32.002)

Author

Palace, Jacqueline, primary, Traboulsee, Anthony, additional, Saiz, Albert, additional, De Seze, Jérôme, additional, Kleiter, Ingo, additional, Bennett, Jeffrey L., additional, Stokmaier, Daniela, additional, Klingelschmitt, Gaëlle, additional, Te-ying, Audrey Yeo, additional, Vodopivec, Ivana, additional, and Yamamura, Takashi, additional

Published
2024
Full Text
View/download PDF

16. Myelin-oligodendrocyte glycoprotein antibody-associated disease

Author

Marignier, Romain, Hacohen, Yael, Cobo-Calvo, Alvaro, Pröbstel, Anne-Katrin, Aktas, Orhan, Alexopoulos, Harry, Amato, Maria-Pia, Asgari, Nasrin, Banwell, Brenda, Bennett, Jeffrey, Brilot, Fabienne, Capobianco, Marco, Chitnis, Tanuja, Ciccarelli, Olga, Deiva, Kumaran, De Sèze, Jérôme, Fujihara, Kazuo, Jacob, Anu, Kim, Ho Jin, Kleiter, Ingo, Lassmann, Hans, Leite, Maria-Isabel, Linington, Christopher, Meinl, Edgar, Palace, Jacqueline, Paul, Friedemann, Petzold, Axel, Pittock, Sean, Reindl, Markus, Sato, Douglas Kazutoshi, Selmaj, Krzysztof, Siva, Aksel, Stankoff, Bruno, Tintore, Mar, Traboulsee, Anthony, Waters, Patrick, Waubant, Emmanuelle, Weinshenker, Brian, Derfuss, Tobias, Vukusic, Sandra, and Hemmer, Bernhard

Published
2021
Full Text
View/download PDF

17. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Author

Grand'Maison, Francois, Jacques, Francois, Traboulsee, Anthony, Tyblova, Michaela, Meluzinova, Eva, Ampapa, Radek, Valis, Martin, Hradilke, Pavel, Mareš, Miroslav, Stourac, Pavel, Gross-Paju, Katrin, Laplaud, David, Mathey, Guillaume, Uitdehaag, Bernard, Evdoshenkoo, Evgeny, Popova, Ekaterina, Zakharova, Maria, Totolyan, Natalia, Litvinenko, Igor, Khabirov, Farit, Sivertseva, Stella, Hancinova, Viera, Kantorova, Ema, Gines, Maria Luisa Martinez, Montalban, Xavier, Maduano, Sara Eichau, Meca-Lallana, Jose, Ramió-Torrentà, Lluís, Nehrych, Tetyanna, Pashkovskyy, Valeriy, Moskovko, Sergii, Kalbus, Oleksandr, Khavunka, Marta, Pryshchepa, Volodymyr, Goloborodko, Alla, Wynn, Daniel, Honeycutt, William, Wray, Sibyl, Steingo, Brian, LaGanke, Christopher, Huang, Deren, Hemphill, John Michael, Goldstick, Lawrence, Robertson, Derrick, Reich, Daniel S, Arnold, Douglas L, Vermersch, Patrick, Bar-Or, Amit, Fox, Robert J, Matta, Andre, Turner, Timothy, Wallström, Erik, Zhang, Xinyan, and Khabirov, Farit A

Published
2021
Full Text
View/download PDF

19. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

Author

Wattjes, Mike P, Ciccarelli, Olga, de Stefano, Nicola, Enzinger, Christian, Fazekas, Franz, Filippi, Massimo, Frederiksen, Jette, Gasperini, Claudio, Hacohen, Yael, Kappos, Ludwig, Mankad, Kshitij, Montalban, Xavier, Palace, Jacqueline, Rocca, María A, Sastre-Garriga, Jaume, Tintore, Mar, Vrenken, Hugo, Yousry, Tarek, Barkhof, Frederik, Rovira, Alex, Li, David K B, Traboulsee, Anthony, Newsome, Scott D, Banwell, Brenda, Oh, Jiwon, Reich, Daniel S, Rocca, Maria A, Tintoré, Mar, and Rovira, Àlex

Published
2021
Full Text
View/download PDF

20. Pooled analysis of multiple sclerosis findings on multisite 7 Tesla MRI: Protocol and initial observations.

Author

Harrison, Daniel M., Choi, Seongjin, Bakshi, Rohit, Beck, Erin S., Callen, Alexis M., Chu, Renxin, Silva, Jonadab Dos Santos, Fetco, Dumitru, Greenwald, Matthew, Kolind, Shannon, Narayanan, Sridar, Okar, Serhat V., Quattrucci, Molly K., Reich, Daniel S., Rudko, David, Russell‐Schulz, Bretta, Schindler, Matthew K., Tauhid, Shahamat, Traboulsee, Anthony, and Vavasour, Zachary

Subjects
DATA libraries, IMAGE processing, DATA harmonization, GRAY matter (Nerve tissue), MULTIPLE sclerosis
Abstract

Although 7 T MRI research has contributed much to our understanding of multiple sclerosis (MS) pathology, most prior data has come from small, single‐center studies with varying methods. In order to truly know if such findings have widespread applicability, multicenter methods and studies are needed. To address this, members of the North American Imaging in MS (NAIMS) Cooperative worked together to create a multicenter collaborative study of 7 T MRI in MS. In this manuscript, we describe the methods we have developed for the purpose of pooling together a large, retrospective dataset of 7 T MRIs acquired in multiple MS studies at five institutions. To date, this group has contributed five‐hundred and twenty‐eight 7 T MRI scans from 350 individuals with MS to a common data repository, with plans to continue to increase this sample size in the coming years. We have developed unified methods for image processing for data harmonization and lesion identification/segmentation. We report here our initial observations on intersite differences in acquisition, which includes site/device differences in brain coverage and image quality. We also report on the development of our methods and training of image evaluators, which resulted in median Dice Similarity Coefficients for trained raters' annotation of cortical and deep gray matter lesions, paramagnetic rim lesions, and meningeal enhancement between 0.73 and 0.82 compared to final consensus masks. We expect this publication to act as a resource for other investigators aiming to combine multicenter 7 T MRI datasets for the study of MS, in addition to providing a methodological reference for all future analysis projects to stem from the development of this dataset. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Author

Wingerchuk, Dean M, Banwell, Brenda, Bennett, Jeffrey L, Cabre, Philippe, Carroll, William, Chitnis, Tanuja, de Seze, Jérôme, Fujihara, Kazuo, Greenberg, Benjamin, Jacob, Anu, Jarius, Sven, Lana-Peixoto, Marco, Levy, Michael, Simon, Jack H, Tenembaum, Silvia, Traboulsee, Anthony L, Waters, Patrick, Wellik, Kay E, and Weinshenker, Brian G

Subjects
Eye Disease and Disorders of Vision, Brain Disorders, Autoimmune Disease, Clinical Research, Neurodegenerative, Multiple Sclerosis, Neurosciences, Neurological, Humans, Neuromyelitis Optica, International Panel for NMO Diagnosis, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.

Published
2015

28. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Author

Amato, Maria Pia, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Becher, Burkhard, Bethoux, François, Brandt, Alexander, Brownlee, Wallace, Calabresi, Peter, Chatway, Jeremy, Chien, Claudia, Chitnis, Tanuja, Ciccarelli, Olga, Cohen, Jeffrey, Comi, Giancarlo, Correale, Jorge, De Sèze, Jerome, De Stefano, Nicola, Fazekas, Franz, Flanagan, Eoin, Freedman, Mark, Fujihara, Kazuo, Galetta, Steven, Goldman, Myla, Greenberg, Benjamin, Hartung, Hans-Peter, Hemmer, Bernhard, Henning, Anke, Izbudak, Izlem, Kappos, Ludwig, Lassmann, Hans, Laule, Cornelia, Levy, Michael, Lublin, Fred, Lucchinetti, Claudia, Lukas, Carsten, Marrie, Ruth Ann, Miller, Aaron, Miller, David, Montalban, Xavier, Mowry, Ellen, Ourselin, Sebastien, Paul, Friedemann, Pelletier, Daniel, Ranjeva, Jean-Philippe, Reich, Daniel, Reingold, Stephen, Rocca, Maria Assunta, Rovira, Alex, Schlaerger, Regina, Soelberg Sorensen, Per, Sormani, Maria, Stuve, Olaf, Thompson, Alan, Tintoré, Mar, Traboulsee, Anthony, Trapp, Bruce, Trojano, Maria, Uitdehaag, Bernard, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian, Wheeler-Kingshott, Claudia Gandini, Xu, Junqian, Cohen, Jeffrey A, Reingold, Stephen C, and Weinshenker, Brian G

Published
2019
Full Text
View/download PDF

29. Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Author

Kappos, Ludwig, primary, Traboulsee, Anthony, additional, Li, David K. B., additional, Bar-Or, Amit, additional, Barkhof, Frederik, additional, Montalban, Xavier, additional, Leppert, David, additional, Baldinotti, Anna, additional, Schneble, Hans-Martin, additional, Koendgen, Harold, additional, Sauter, Annette, additional, Wang, Qing, additional, and Hauser, Stephen L., additional

Published
2023
Full Text
View/download PDF

30. Grey Matter Segmentation in Spinal Cord MRIs via 3D Convolutional Encoder Networks with Shortcut Connections

Author

Porisky, Adam, Brosch, Tom, Ljungberg, Emil, Tang, Lisa Y. W., Yoo, Youngjin, De Leener, Benjamin, Traboulsee, Anthony, Cohen-Adad, Julien, Tam, Roger, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Cardoso, M. Jorge, editor, Arbel, Tal, editor, Carneiro, Gustavo, editor, Syeda-Mahmood, Tanveer, editor, Tavares, João Manuel R.S., editor, Moradi, Mehdi, editor, Bradley, Andrew, editor, Greenspan, Hayit, editor, Papa, João Paulo, editor, Madabhushi, Anant, editor, Nascimento, Jacinto C., editor, Cardoso, Jaime S., editor, Belagiannis, Vasileios, editor, and Lu, Zhi, editor

Published
2017
Full Text
View/download PDF

31. Hierarchical Multimodal Fusion of Deep-Learned Lesion and Tissue Integrity Features in Brain MRIs for Distinguishing Neuromyelitis Optica from Multiple Sclerosis

Author

Yoo, Youngjin, Tang, Lisa Y. W., Kim, Su-Hyun, Kim, Ho Jin, Lee, Lisa Eunyoung, Li, David K. B., Kolind, Shannon, Traboulsee, Anthony, Tam, Roger, Hutchison, David, Editorial Board Member, Kanade, Takeo, Editorial Board Member, Kittler, Josef, Editorial Board Member, Kleinberg, Jon M., Editorial Board Member, Mattern, Friedemann, Editorial Board Member, Mitchell, John C., Editorial Board Member, Naor, Moni, Editorial Board Member, Pandu Rangan, C., Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Terzopoulos, Demetri, Editorial Board Member, Tygar, Doug, Editorial Board Member, Weikum, Gerhard, Series Editor, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Descoteaux, Maxime, editor, Maier-Hein, Lena, editor, Franz, Alfred, editor, Jannin, Pierre, editor, Collins, D. Louis, editor, and Duchesne, Simon, editor

Published
2017
Full Text
View/download PDF

32. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

Author

Correale, Jorge, Caride, Alejandro, Deri, Norma H., Ballario, Carlos, Broadley, Simon, Kneebone, Chris, Barnett, Michael, Pollard, John, Hodgkinson, Suzanne, Kermode, Allan, Macdonell, Richard, King, John, Butzkueven, Helmut, Lechner-Scott, Jeannette, Saines, Noel, Slee, Mark, Plummer, Chris, Willekens, Barbara, Vanopdenbosch, Ludo, Belachew, Shibeshih, Phan-Ba, Rémy, Delvaux, Valérie, Bissay, Veronique, Debruyne, Jan, Decoo, Danny, Crols, Roeland, Symons, Anoek, Nagels, Guy, Van Pesch, Vincent, Sindic, Christian, Dubois, Benedicte, Medaer, Robert, D'Hooghe, Marie, Guillaume, Daniel, De Smet, Eric, Seeldrayers, Pierrette, Lysandropoulos, Andreas, Vokaer, Mathieu, Geens, Karine, Willems, Christina, Denayer, Pierre, Bureau, Michel, Retif, Cecile, Dupuis, Michel, Bouquiaux, Olivier, Vanderdonckt, Patrick, van Landegem, William, Caekebeke, Jo, Van Ingelghem, Erwin, Peeters, Katelijne, Gerard, Pascale, de Noordhout, Alain Maertens, Desfontaines, Philippe, Urbain, Etienne, Declercq, Inge, Van Wijmeersch, Bart, Vanroose, Erwin, Wibail, Alain, Barthomolé, Emmanuel, Ursell, Melanie, Sweet, Margaret Elizabeth, Howse, David, Jichici, Draga, Shawush, Melad, Namaka, Mike, Traboulsee, Anthony, Hashimoto, Stan, Lo, Raymond, Marchetti, Paul, Lapierre, Yves, Jacques, Francois, MacLean, Gregg, Bhan, Virender, Duquette, Pierre, Stewart, Bradley, Paulseth, John, Kremenchutzky, Marcelo, Vorobeychik, Galina, O'Connor, Paul, Grand'Maison, François, Havrdova, Eva, Meluzinová, Eva, Valis, Martin, Talab, Radomír, Stourac, Pavel, Zapletalová, Olga, Dufek, Michal, Sládková, Vladimíra, Novotna, Alena, Vancurová, Romana, Lhotaková, Libuse, Fiedler, Jiri, Vachova, Marta, Dolezil, David, Stetkarova, Ivana, Rehankova, Adela, Psenica, Petr, Ulehlova, Veronika, Feketova, Sona, Skoda, Ondrej, Färkkilä, Markus, Taneli, Sarasoja, Koivisto, Keijo, Seppä, Juha Matti, Airas, Laura, Elovaara, Irina, Hartikainen, Päivi, Pirttila, Tuula, Louchart, Pierre, Ille, Olivier, Thenint, Jean philippe, Godet, Etienne, Vioud, Marcel Maillet, Colamarino, Renato, Gugenheim, Michel, Grimaud, Jerome, Kopf, Audrey, Billy, Christophe, Huttin, Bernard, Borsotti, Jean paul, Devos, Philippe, Kendjuo, Jean bertin N, Verier, Albert, Chapuis, Stephane, Daluzeau, Nathalie, Angibaud, Gilles, Uriot, Marie-Sylvie Artaud, Ziegler, François, Sellal, François, Moulignier, Antoine, Lavenu, Isabelle, Ismail, Samir, Devy, Richard, Suceveanu, Manuel, Wagner, Marc, Marcel, Sebastien, Derouiche, Faycal, Mostoufizadehghalamfarsa, Sohrab, Delalande, Sophie, Ruggieri, Irene, Van Nieuwenhuyse, Catherine Bossu, Nifle, Chantal, Ondze, Basile, Vasilescu, Carmen Gurau, Vongsouthi, Cyrille, Coustans, Marc, Anne, Olivier, Amevigbe, Josephine, Servan, Jerome, Merienne, Marc, Eck, Philippe, Berroir, Stephane, Busson, Philippe, Barroso, Bruno, Larrieu, Jean-Marc, Giendaj, Catherine Louvet, Malkoun, Imad, Hautecoeur, Patrick, Kwiatkowski, Arnaud, Pouliquen, Andre, Garrigues, Guillaume, Delerue, Olivier, Giraud, Pierric, Gere, Julien, Vaunaize, Jean, Dereeper, Olivier, Seiller, Nicolas, Alsassa, Roger, Vlaicu, Mihaela, Neuville, Veronique, Faucheux, Jean Marc, Bernady, Patricia, Fanjaud, Guy, Viallet, François, Schroeter, Michael, Schlemilch-Paschen, Sylke, Lange, Thomas, Bohr, Kin-Arno, Jendroska, Klaus, Rehkopf, Elisabeth, Bergmann, Arnfin, Kleinschnitz, Christoph, Postert, Thomas, Scholz, Peter, Mauz, Uwe, Stratmann, Hubert, Siefjediers, Veneta, Prantl, Martin, Gehring, Klaus, Zellner, Ruth, Junge, Kathrin, Zellner, Anton, Bacay, Valerina, Schlegel, Eugen, Polzer, Udo, Strauss, Erik, Link, Andreas, Stenzel, Christoph, Freidel, Matthias, Drews, Joachim, Neudert, Christian, Schmitz, Frank, Jaeger, Joachim, Masri, Said, Heuberger, Wolfgang, Trausch, Beate, Ruhnke, Oliver, Scarel, Serena, Bach, Kathlen, Ernst, Michael, Landefeld, Harald, Richter, Nils, Schmidt, Stephan, Krause, Michaela, Dressel, Alezander, Ruth, Roland, Anvari, Kerstin, Gossling, Jens, Schenk, Christoph, Tiedge, Oliver, Bode, Lutz, Eder, Hans-Thomas, Pfeffer, Oliver, Krug, Reinhard, Lassek, Christoph, Fleischer, Eberhard, Meuth, Sven, Klotz, Luisa Hildegard, Peglau, Ines, Kukowski, Borries, Herting, Birgit, Guthke, Kersten, Schierenbeck, Jurgen, Brockmeier, Bernd, Albrecht, Holger, Wuttke, Matthias, Augspach-Hofmann, Regine, Gunther, Stefan, Redbrake, Martin, Franke, Christian, Buchner, Klaus, Gratz, Thomas, Horn, Rolf, Doemges, Frank, Schreiber, Martin, Brosch, Thomas, Horn, Markus, Kittlitz, Matthias, Vulturius, Gabriele, Hinse, Paul, Malessa, Rolf, Wiehler, Stephan, Katsarava, Zaza, Kastrup, Oliver, Kausch, Ulrich, Gullekes, Martin, Fickinger, Markus, Wenzel, Wilhelm, Botefur, Ingolf C., Reifschneider, Gerd, Rauer, Sebastian, Lang, Michael, Harms, Lutz, Eckhardt, Ulrich, Cursiefen, Simone, Linker, Ralf, Angstwurm, Klemens, Haas, Judith, Schuetze, Ivo, Rohm, Eva, Stienker-Fisse, H., Sailer, Michael, Bohringer, Johannes, Maurer, Mathias, Bause, Eberhard, Wersching, Ronald, Dachsel, Reinhardt, Domke, Sylke, Hoffman, Frank, Tackenberg, Bjorn, Roch, Kerstin, Ziebold, Uwe, Kallmann, Boris, Buehler, Bernhard, Faiss, Judith, Faiss, Juergen, Schimrigk, Sebastian, Menges, Christian, Knop, Karl Christian, Koehler, Wolfgang, Siever, Arno, Bufler, Johannes, Gramsl, Georg, Kuhnler, Benedicta, Maschke, Matthias, Stogbauer, Florian, Staude, Lisa, Bethke, Florian, Bitsch, Andreas, Harmjanz, Arndt D., Windsheimer, Jorg, Kieseier, Bernd C., Berkenfeld, Ralf, Tumani, Hayrettin, Kirsch, Michael, Wildemann, Brigitte, Daniels, Regina, Gottwald, Klaus, Elias, Wolfgang-Gerhard, Hoffmann, Olaf, Schwab, Matthias, Pilz, Christopher, Klostermann, Fabian, Hellwig, Kerstin, Berthele, Achim, Bayas, Antonios, Molitor, Daniel, Grothe, Christoph, Wagner, Bert, Karageorgiou, Klimentini, Mitsikostas, Dimosthenis, Kodounis, Antonios, Plaitakis, Andreas, Papadimitriou, Alexandros, Grigoriadis, Nikolaos, Vlaikidis, Nikolaos, Koutlas, Evaggelos, Kyritsis, Athanassios, Papathanassopoulos, Panagiotis, Makris, Nikolaos, Tavernarakis, Antonios, Scarpini, Elio, Montanari, Enrico, Marrosu, Maria Giovanna, Trojano, Maria, Amato, Maria Pia, Rottoli, Mariarosa, Lugaresi, Alessandra, Florio, Ciro, Gasperini, Claudio, Grimaldi, Luigi, Millefiorini, Enrico, Koudriavtseva, Tatiana, Perla, Franco, Mantegazza, Renato, Bertolotto, Antonio, Ghezzi, Angelo, Aguilar, Sandra Quinones, Eisenberg, Eli Skromne, Lopez, Leondardo Llamas, Estudillo, Rocio Marquez, Schrijver, H.M., Wittebol, M.C., Baart, J.C., van Golde, A.E.L., Hengstman, G.J.D., Pop, P.H.M., Bos (Geldrop), M., Medaer, R., Schyns-Soeterboek, Angelique, van der Zwart, A., van Diepen, A.J.H., Verheul, G.A.M., Verhagen, W.I.M., Bos (Helmond), M., Witjes, R.J.G.M., Sinnige, L.G.F., van Munster, E.Th.L., Sanders, E.A.C.M., van Dijl, Ron, Hupperts, R.M.M., Frequin, S.T.F.M., Visser, L.H., Henselmans, J.M.L., Moll, J.W.B., Midgard, Rune, Myhr, Kjell Morten, Edland, Astrid, Telstad, Wenche, Hognestad, Tone, Lund, Christian, Hovdal, Harald, Kamaljit, Kaur, Schepel, Jan, Hogenesch, Roelfien Ida, Schüler, Stephan, Odeh, Francis, Alstadhaug, Karl B., Korsgaard, Olav, Farbu, Elisabeth, Ingvaldsen, Teis Barclay, Soares (SCO), Diana, Rente, José, Guerra, José Manuel Costa, Morganho, Armando, Leitão, António, de Sá, João, Sá, Maria José, Marques, Pinto, Veloso, Mário, Baptista, Miguel Viana, Szilasiová, Jarmila, Copikova-Cudrakova, Daniela, Prochazkova, Lubica, Klimová, Eleonóra, Donath, Vladimir, Brozman, Miroslav, Ramo, Cristina, Ruiz, Domingo Pérez, Hernández, Carmen Calles, Sola, María Eugenia Marzo, Moro, Roberto Suarez, Vidal, Jose Antonio, Rodríguez, Ana Belén Caminero, Ozaeta, Gisela Martin, Nadal, Jordi Batlle, Esquide, Amaya Alvarez de Arcaya, Urtaza, Javier Olascoaga, Martínez-Yélamos, Sergio, Arbizu, Txomin, Torrenta, Lluis Ramio i, Boggild, Mike, Wilson, Martin, Al-Araji, Adnan, Nicholas, Richard, Harrower, Timothy, Redmond, Ian, Wolf, Tilo, Osei-Bonsu, Michael, Mazibrada, Gordon, Rog, David, Cottrell, David, Constantinescu, Cris, Gray, Orla, Belhag, Mohamed, Shehu, Abdullah, Rashid, Waqar, Duddy, Martin, Kappos, Ludwig, Wiendl, Heinz, Spelman, Tim, Pellegrini, Fabio, Chen, Yi, Dong, Qunming, and Koendgen, Harold

Published
2018
Full Text
View/download PDF

34. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Author

Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, and Cohen, Jeffrey A

Published
2018
Full Text
View/download PDF

36. Deep Learning of Brain Lesion Patterns for Predicting Future Disease Activity in Patients with Early Symptoms of Multiple Sclerosis

Author

Yoo, Youngjin, Tang, Lisa W., Brosch, Tom, Li, David K. B., Metz, Luanne, Traboulsee, Anthony, Tam, Roger, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Carneiro, Gustavo, editor, Mateus, Diana, editor, Peter, Loïc, editor, Bradley, Andrew, editor, Tavares, João Manuel R. S., editor, Belagiannis, Vasileios, editor, Papa, João Paulo, editor, Nascimento, Jacinto C., editor, Loog, Marco, editor, Lu, Zhi, editor, Cardoso, Jaime S., editor, and Cornebise, Julien, editor

Published
2016
Full Text
View/download PDF

37. Corpus Callosum Segmentation in Brain MRIs via Robust Target-Localization and Joint Supervised Feature Extraction and Prediction

Author

Tang, Lisa Y. W., Brosch, Tom, Liu, XingTong, Yoo, Youngjin, Traboulsee, Anthony, Li, David, Tam, Roger, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Ourselin, Sebastien, editor, Joskowicz, Leo, editor, Sabuncu, Mert R., editor, Unal, Gozde, editor, and Wells, William, editor

Published
2016
Full Text
View/download PDF

39. Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study

Author

Martin, Nancy, Traboulsee, Anthony L., Machan, Lindsay, Klass, Darren, Ellchuk, Tasha, Zhao, Yinshan, Knox, Katherine B., Kopriva, David, Lala, Shantilal, Nickel, Darren, Otani, Robert, Perera, Warren R., Rauscher, Alexander, Sadovnick, A. Dessa, Szkup, Peter, and Li, David K.

Published
2017
Full Text
View/download PDF

42. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD

Author

Cook, Lawrence J., Rose, John W., Alvey, Jessica S., Jolley, Anna Marie, Kuhn, Renee, Marron, Brie, Pederson, Melissa, Enriquez, Rene, Yearley, Jeff, McKechnie, Stephen, Han, May H., Tomczak, Anna J., Levy, Michael, Mealy, Maureen A., Coleman, Jessica, Bennett, Jeffrey L., Johnson, Ruth, Barnes-Garcia, Myka, Traboulsee, Anthony L., Carruthers, Robert L., Lee, Lisa Eunyoung, Schubert, Julia J., McMullen, Katrina, Kister, Ilya, Rimler, Zoe, Reid, Allyson, Sicotte, Nancy L., Planchon, Sarah M., Cohen, Jeffrey A., Ivancic, Diane, Sedlak, Jennifer L., Sand, Ilana Katz, Repovic, Pavle, Amezcua, Lilyana, Pruitt, Ana, Amundson, Erika, Chitnis, Tanuja, Mullin, Devin S., Klawiter, Eric C., Russo, Andrew W., Riley, Claire S., Onomichi, Kaho B., Levine, Libby, Nelson, Katherine E., Nealon, Nancy M., Engel, Casey, Kruse-Hoyer, Mason, Marcille, Melanie, Tornes, Leticia, Rumpf, Anne, Greer, Angela, Kenneally Behne, Megan, Rodriguez, Renee R., Behne, Daniel W., Blackway, Derek W., Coords, Brian, Blaschke, Terrence F., Sheard, Judy, Smith, Terry J., Behne, Jacinta M., and Yeaman, Michael R.

Published
2019
Full Text
View/download PDF

43. Deep Convolutional Encoder Networks for Multiple Sclerosis Lesion Segmentation

Author

Brosch, Tom, Yoo, Youngjin, Tang, Lisa Y. W., Li, David K. B., Traboulsee, Anthony, Tam, Roger, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Navab, Nassir, editor, Hornegger, Joachim, editor, Wells, William M., editor, and Frangi, Alejandro F., editor

Published
2015
Full Text
View/download PDF

44. Corpus Callosum Segmentation in MS Studies Using Normal Atlases and Optimal Hybridization of Extrinsic and Intrinsic Image Cues

Author

Tang, Lisa Y. W., Hamarneh, Ghassan, Traboulsee, Anthony, Li, David, Tam, Roger, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Kittler, Josef, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, Navab, Nassir, editor, Hornegger, Joachim, editor, Wells, William M., editor, and Frangi, Alejandro F., editor

Published
2015
Full Text
View/download PDF

45. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

Author

Kowalec, Kaarina, Wright, Galen E. B., Drögemöller, Britt I., Aminkeng, Folefac, Bhavsar, Amit P., Kingwell, Elaine, Yoshida, Eric M., Traboulsee, Anthony, Marrie, Ruth Ann, Kremenchutzky, Marcelo, Campbell, Trudy L., Duquette, Pierre, Chalasani, Naga, Wadelius, Mia, Hallberg, Pär, Xia, Zongqi, De Jager, Philip L., Denny, Joshua C., Davis, Mary F., Ross, Colin J. D., Tremlett, Helen, and Carleton, Bruce C.

Published
2018
Full Text
View/download PDF

48. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results

Author

Wilken, Jeffrey, primary, Traboulsee, Anthony, additional, Nelson, Flavia, additional, Ionete, Carolina, additional, Kolind, Shannon, additional, Fratto, Timothy, additional, Kane, Robert, additional, Gandhi, Roopali, additional, Rawlings, Andreea M., additional, Roesch, Nora, additional, Ozog, Mark A., additional, and DeLuca, John, additional

Published
2023
Full Text
View/download PDF

49. Long-term Efficacy of Satralizumab in Adults with Aquaporin-4-IgG-seropositive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from SAkuraMoon (S5.001)

Author

Traboulsee, Anthony, primary, Kleiter, Ingo, additional, Palace, Jacqueline, additional, Fujihara, Kazuo, additional, Saiz, Albert, additional, Vodopivec, Ivana, additional, Klingelschmitt, Gaelle, additional, Marcillat, Carole, additional, and Bennett, Jeffrey, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results